Immunomic Therapeutics’ CBO to present at the 14th Annual Biotech Showcase Event
ROCKVILLE, Md.--(BUSINESS WIRE)--Jan 6, 2022--
Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today that the company will present at the 14 th Annual Biotech Showcase Event, January 10-12 and January 17-19, virtually. Chief Business Officer at ITI, Bob Newman, will present a talk titled, “Pioneering the Next Generation of Immunotherapies.” Mr. Newman will discuss ITI’s investigational UNiversal Intracellular Targeted Expression (UNITE) platform and its application in immuno-oncology, specifically glioblastoma multiforme (GBM). ITI’s technology platform has the potential to utilize the body’s natural biochemistry to develop a broad immune response and is currently being employed in a Phase II clinical trial as a cancer immunotherapy.
Presentation details are as follows:
Bob Newman, Chief Business Officer of Immunomic Therapeutics, Inc.
Pioneering the Next Generation of Immunotherapies
Date: Monday, January 10, 2022
Track: Franciscan D
ITI’s investigational UNITE platform, or UNiversal Intracellular Targeted Expression, works by fusing pathogenic antigens with the Lysosomal Associated Membrane Protein 1 (LAMP1), an endogenous protein in humans, for immune processing. In this way, ITI’s vaccines (DNA or RNA) have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach puts UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. UNITE is currently being employed in a Phase II clinical trial as a cancer immunotherapy. ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Preclinical data is currently being developed to explore whether LAMP1 nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response.
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body’s natural biochemistry to develop vaccines that have the potential to generate broad immune responses. The UNITE platform has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including targeting viral antigens, cancer antigens, and producing antigen-derived antibodies as biologics. In 2020, an investment of over $77M by HLB Co., LTD, a global pharmaceutical company, enabled ITI to accelerate application of its immuno-oncology platform, in particular to glioblastoma multiforme, and rapidly advance other key candidates in the pipeline. The Company has built a pipeline from UNITE with four wholly owned oncology programs, the lead of which is in a Phase 2 clinical study for Glioblastoma Multiforme (GBM). ITI has formed several academic collaborations with leading Immuno-oncology researchers at Duke University and the University of Florida. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit www.immunomix.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20220106005718/en/
CONTACT: Company:Melissa Kemp
KEYWORD: MARYLAND UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: ONCOLOGY HEALTH GENERAL HEALTH CLINICAL TRIALS RESEARCH SCIENCE BIOTECHNOLOGY
SOURCE: Immunomic Therapeutics, Inc.
Copyright Business Wire 2022.
PUB: 01/06/2022 12:05 PM/DISC: 01/06/2022 12:06 PM